Stockscreener 앱 받기
214.35
1.11%
-2.40
Abbvie Inc 주식(ABBV)의 최신 뉴스
Could Buying This Stock Today Pay Off Big Over the Next 5 Years? - Finviz
Could Buying This Stock Today Pay Off Big Over the Next 5 Years? - The Motley Fool
Key facts: AbbVie to invest $100B in U.S. research; Phase 3 trial shows progress - TradingView — Track All Markets
AbbVie stock heads into long weekend lower after mixed Epkinly trial readout; earnings next - TechStock²
PRESCRIPTION DRUGS—N.D. Ill.: Complaint that AbbVie violated state consumer protection statutes dismissed - VitalLaw.com
AbbVie Call Options Spike 2,599%: Tracking the Big Bet - Finviz
AbbVie and Genmab Advance Epcoritamab with Significant PFS Improvement in DLBCL Trial - Intellectia AI
AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst - TechStock²
AbbVie Announces Topline Results for Epcoritamab from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - Investing News Network
AbbVie (ABBV) Phase 3 Trial Shows Progression-Free Survival Impr - GuruFocus
Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study - TradingView — Track All Markets
Genmab down after trial data for AbbVie-partnered Epkinly in B-cell lymphoma - Seeking Alpha
AbbVie (ABBV) and Genmab Advance Epcoritamab Trials for Lymphoma - GuruFocus
AbbVie reports mixed results in phase 3 lymphoma trial By Investing.com - Investing.com Canada
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) - Yahoo Finance
AbbVie Expands Oncology Pipeline With First-in-Human ABBV-711 Trial in Advanced Squamous Tumors - TipRanks
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Glaukos (GKOS) - The Globe and Mail
Zacks Research Comments on AbbVie's Q1 Earnings (NYSE:ABBV) - MarketBeat
JPM26: AbbVie highlights growth drivers as it moves away from Humira dependency - Pharmaceutical Technology
Rx Rundown: Nvidia, Johnson & Johnson, AbbVie and more - Medical Marketing and Media
AbbVie Inc.'s (NYSE:ABBV) institutional investors lost 3.3% last week but have benefitted from longer-term gains - Yahoo Finance
Investors Purchase Large Volume of AbbVie Call Options (NYSE:ABBV) - MarketBeat
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts - Yahoo Finance
AbbVie (NYSE:ABBV) Shares Down 2.4%Time to Sell? - MarketBeat
Atopic Dermatitis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie, Allergan - Barchart.com
AbbVie stock slides 2% as obesity push takes center stage at JPM conference - TechStock²
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
J.P. Morgan: AbbVie Still Aims To Be A Major Obesity Player – With A Lift From Botox - Citeline News & Insights
AbbVie Advances Obesity Pipeline With Completion of First-in-Human GUB014295 Trial - TipRanks
The Zacks Analyst Blog Highlights AbbVie, Intel, Boeing and Tandy Leather Factory - Yahoo Finance
BMO Capital reiterates Outperform rating on AbbVie stock amid growth By Investing.com - Investing.com UK
AbbVie Inc. $ABBV Shares Bought by Meritage Portfolio Management - MarketBeat
Why AbbVie Has Committed $100bn to US Medicine Supply Chains - Procurement Magazine
How AbbVie’s $100bn Investment Reshapes Pharma Supply Chains - Supply Chain Digital Magazine
AbbVie’s US$100bn Deal Could Transform US Healthcare Access - Healthcare Digital
Conning Inc. Decreases Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Seeks To Grow Obesity Drug Portfolio — Retail Touts Drugmaker As Big Competition To Lilly - Stocktwits
AbbVie: stepping up obesity treatments with an alternative approach to GLP-1 - marketscreener.com
Rep. Julia Letlow Sells Off Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie stock in focus after hours as it eyes obesity market — what to watch next - TechStock²
Top Research Reports for AbbVie, Intel & Boeing - Yahoo Finance
AbbVie plans to build out its presence in obesity market - Reuters
AbbVie Reaches Agreement With Trump Administration, Joining MFN Initiatives - Pharmacy Times
AbbVie to invest $100 billion in the U.S in exchange for tariff exemptions - The American Bazaar
JP Morgan 2026: AbbVie Advances its Pipeline - PharmExec.com
Key facts: AbbVie Reports Growth in Immunology, Neuroscience; Targets Weight-Loss Market - TradingView — Track All Markets
AbbVie sets sights on immunology, neurology dominance - Crain's Chicago Business
AbbVie Bets Big on Chinese Cancer Drug in $5.6 Billion Licensing Deal - Caixin Global
AbbVie Joins TrumpRx in Exchange for Tariff Relief and Pricing Flexibility - Pharmaceutical Commerce
AbbVie (ABBV) Rises on Agreement for Drug Pricing and Investment Commitment - GuruFocus
Ex-Dividend Reminder: AbbVie, Dime Community Bancshares and MidWestOne Financial Group - Nasdaq
AbbVie pledges $100B to US production in drug pricing deal with Trump - Construction Dive
Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy? - Yahoo Finance
Stephens Inc. AR Boosts Position in AbbVie Inc. $ABBV - MarketBeat
Retirement Planning Group LLC Buys 6,958 Shares of AbbVie Inc. $ABBV - MarketBeat
Kera Capital Partners Inc. Makes New Investment in AbbVie Inc. $ABBV - MarketBeat
AbbVie’s Trump Deal Unlocks US$100bn for R&D & Manufacturing - Manufacturing Digital
Robeco Schweiz AG Decreases Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie To Buy Device Manufacturing Facility From West Pharmaceutical Services - Med Device Online
AbbVie inks USD 5.6bn global licensing deal with Chinese biotech for cancer therapy - medwatch.com
AbbVie strikes deal with Trump, pledges USD 100bn investment over 10 years - medwatch.com
Trump administration strikes deal with AbbVie to cut costs of certain drugs - KCRA
Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B - Stocktwits
Key facts: AbbVie signs Medicaid deal; banker charged with insider trading; UAE launches mental health campaign - TradingView — Track All Markets
AbbVie and Trump administration reach agreement on drug prices, tariffs - Daily Herald
AbbVie, RemeGen Partner on Novel Bispecific Antibody for Advanced Tumors - Contract Pharma
AbbVie news: Trump administration strikes deal with North Chicago-based company to cut costs of certain drugs - ABC7 Chicago
AbbVie Signs US Deal to Cut Drug Prices, Secure Tariff Exemptions - Yahoo Finance
ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon - Yahoo Finance
9.12%
1.93%
자본화:
|
볼륨(24시간):